These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12851994)

  • 1. Irbesartan-associated persistent edema of the eyelids, face, and neck.
    Cohen PR
    J Drugs Dermatol; 2002 Dec; 1(3):329-30. PubMed ID: 12851994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute pancreatitis associated with angiotensin II receptor antagonists.
    Fisher AA; Bassett ML
    Ann Pharmacother; 2002 Dec; 36(12):1883-6. PubMed ID: 12452749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could irbesartan trigger autoimmune cholestatic hepatitis?
    Annicchiarico BE; Siciliano M
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):247-8. PubMed ID: 15674105
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug points: prolonged cholestasis associated with irbesartan.
    Hariraj R; Stoner E; Jader S; Preston DM
    BMJ; 2000 Sep; 321(7260):547. PubMed ID: 10968816
    [No Abstract]   [Full Text] [Related]  

  • 5. Lichenoid drug eruption due to an antihypertonic drug containing irbesartan and hydrochlorothiazide.
    Pfab F; Athanasiadis GI; Kollmar A; Ring J; Ollert M
    Allergy; 2006 Jun; 61(6):786-7. PubMed ID: 16677251
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute oliguric renal failure associated with angiotensin II receptor antagonists.
    Lee HY; Kim CH
    Am J Med; 2001 Aug; 111(2):162-3. PubMed ID: 11501548
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
    Man in't Veld AJ
    J Hypertens Suppl; 1997 Dec; 15(7):S27-33. PubMed ID: 9532518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angioedema due to irbesartan].
    Rodríguez Conesa A; Matilla Fernández B; Gozalo Reques F
    Rev Esp Cardiol; 2001 Apr; 54(4):532. PubMed ID: 11282063
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug clinics. Drug of the month. Irbesartan (Aprovel)].
    Kulbertus H
    Rev Med Liege; 1999 Feb; 54(2):125-7. PubMed ID: 10221067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Irbesartan-induced acute hepatitis].
    Foruny Olcina JR; Moreira Vicente VF; Gómez García M; Morell Hita JL
    Gastroenterol Hepatol; 2004 Feb; 27(2):71-2. PubMed ID: 14733885
    [No Abstract]   [Full Text] [Related]  

  • 13. A look through the new therapeutic window: irbesartan.
    Waeber B; Brunner HR
    J Hypertens Suppl; 1998 Sep; 16(7):S11-6. PubMed ID: 9855026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Irbesartan induced acute hepatitis: one case].
    Péron JM; Robic MA; Bureau C; Vinel JP
    Gastroenterol Clin Biol; 2005; 29(6-7):747-8. PubMed ID: 16149188
    [No Abstract]   [Full Text] [Related]  

  • 15. [Acute renal failure associated with irbesartan].
    Anglada Pintado JC; Gallego Puerto P; Zapata López A; Cayón Blanco M
    Med Clin (Barc); 1999 Sep; 113(9):358-9. PubMed ID: 10562934
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
    Neutel JM; Germino FW; Smith D
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
    Mörtsell D; Malmqvist K; Held C; Kahan T
    J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.